GW Pharmaceuticals Announces Agreement on Sativex Pricing in Germany
GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, «GW») announced today that agreement for a revised
«We are pleased to have a positive outcome to discussions that result in an acceptable reimbursement price for Sativex® inGermany, Europe’s largest potential market for Sativex®. This agreement ensures that people suffering from Multiple Sclerosis spasticity in Germany will have
It is estimated that approximately 4,000 patients are currently being treated with Sativex in Germany.
«Almirall is committed to meeting the needs of MS patients and this is the reason we have been determined over recent months to achieve an appropriate resolution of the reimbursement price in Germany," said Farid Taha, General Manager of Almirall Hermal Company. «Sativex® represents an important advance in the symptomatic treatment of MS spasticity and this new agreement provides doctors and patients inGermany with the necessary assurance that Sativex® represents not only a recognised therapeutic benefit, but will also be available on prescription for the